A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Mayo Clinic
OHSU Knight Cancer Institute
Fate Therapeutics
Odonate Therapeutics, Inc.
Northwestern University